Primary tabs

PureTech Receives Up To $36 Million from Roche to Develop Oral Delivery of Antisense Oligonucleotides
Post date: July 20, 2018 - 9:43am
Sage Bionetworks Launches Platform to Crowdsource the Evaluation of Curated Alzheimer’s Disease Genomic Analysis
Post date: July 20, 2018 - 9:25am
FDA to Consider Foreign Drug Importation When Lack of Competition or Supply Problems Threaten Access
Post date: July 19, 2018 - 12:18pm
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Post date: July 19, 2018 - 10:07am
Bristol-Myers Squibb and Gritstone Oncology Announce Collaboration to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors
Post date: July 19, 2018 - 9:44am
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Post date: July 19, 2018 - 9:31am
FDA Approves First Cancer Drug Under New Real Time Review Program
Post date: July 18, 2018 - 1:20pm
Cellectar Reports 33% Overall Response Rate in Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients
Post date: July 18, 2018 - 9:58am
Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)
Post date: July 18, 2018 - 9:43am
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
Post date: July 18, 2018 - 9:27am

Pages